Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
Hosted on MSN2d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback